Dr Sun 讲的挺对，机体状态恢复一下，做免疫治疗比较好。您的亲属，经过化疗 自体骨髓移植，又有病情发展，估计可能没达到或短暂缓解。很可能是难治一类的淋巴瘤。淋巴瘤基本有两大类， 何杰金（HL）和非何杰金（NHL）淋巴瘤，前者预后较好，后者中也有不少类型，其中一些类型比较难治，预后不好。不知道您亲属什么类型。PD-1或类似PD-1的抗体药物，在淋巴瘤里已开始临床试验。 其中Nivolumab 和 pembrolizumab效果还不太明确。另一种Pidilizumab疗效看起来挺好。如果经济条件允许您亲属可以试试，如 Dr.Sun讲的，机体状态得回复，下边的Pidilizumab治疗 也是在减少肿瘤负荷量前提下做的。
报告说：A phase II single-arm international study of pidilizumab in relapsed or refractory DLBCL or primary mediastinal B-cell lymphoma （弥漫大B细胞淋巴瘤 和 原发性纵隔B细胞淋巴瘤，这两类都不太好治疗） after autologous stem cell transplant was performed with the rationale that PD-1 blockade post-transplant would be effective due to low-volume disease and the potential for immune remodeling. The study included 66 patients. In the 35 patients with measurable disease, the overall response rate was 51%, with 34% achieving complete response and 37% achieving stable disease. Correlative studies demonstrated an increase in PD-L1-bearing circulating lymphocytes, apparent 24 h after pidilizumab treatment, and sustained until almost 16 weeks. Subsequently, the drug was evaluated in conjunction with rituximab in a phase II single-arm open label study of 29 eligible patients with relapsed, refractory follicular lymphoma. There were no highgrade treatment-related adverse events, and the overall response rate was 66%, with an impressive 52% complete response rate.
